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1. Abstract
This is a review of the relationship of autoimmune diseases to cancer from two perspectives. The first is to
examine which autoimmune diseases are often associated with increased risk of the development of a malignancy. The
second is to review which common cancers confer an increased risk of developing an autoimmune disease. In addition,
some novel approaches to cancer immunotherapy are discussed.

2. Introduction

Emerging evidence has implicated certain environmental factors such as infections, and dietary
proteins in the pathogenesis of many autoimmune diseases and cancer 1. This article attempts to correlate the common
factors, with recent updates from the literature. There are many unresolved observations. For example, autoimmune
thyroid disease is associated with multiple myeloma [odds ratio = 5.68, 95% confidence interval: 1.69-19.13] 2. There is
also a case report of autoimmune disease occurring in a long-term survivor with metastatic colon carcinoma treated
with a novel chemo-immunotherapy regimen 3. GOLFIG-1 is a new translational anticancer regimen based on the
combined use of gemcitabine, oxalipatin, levofolinic acid and infusional 5-fluorouracil and subcutaneous
administration of immunoadjuvant cytokines, granulocyte-macrophage-colony stimulating factor (GM-CSF) and very
low dose interleukin-2 (IL-2). The patient responded to the GOLFIG regimen but developed discoid lupus
erythematosus.

Primary immunodeficiencies (PIDs) are genetic disorders that predispose to frequent and severe infections,
autoimmunity and cancer 4. The expanded life span of such patients increases the overall risk for developing cancer,
which is now estimated at 4-25%. The type of malignancy depends on the primary immunodeficiency, the age of the
patient and possibly viral infection. Non-Hodgkin lymphomas predominate, accounting for 60% of cases. The PIDs
known to be associated with increased incidence of malignancy are: common variable immunodeficiency, IgA
deficiency, DNA repair disorders, as severe combined immunodeficiency, Wiskott Aldrich syndrome, Klinefelter’s
syndrome, Chediak-Higashi syndrome, ataxia telangiectasia syndrome. Acquired immunodeficiency diseases include
iatrogenic immunosuppression as in organ transplant recipients, acquired immunodeficiency syndrome caused by
human immunodeficiency virus (HIV), and hypogammaglobulinemia. HTLV-1 is associated with adult T cell
leukemia-lymphoma (ATLL). HIV produces AIDS and the resultant immune deficiency is associated with high-grade

B-cell lymphoma. Around 60 years ago, infants were given thymic irradiation. Autoimmune diseases appear later in
life. The disrupted immune system also predisposes them to cancer.
There may be many mediators and receptors involved. IL-21 is a type I cytokine 5 produced by activated
CD4(+) T cells, NKT cells, and Th17 cells. It has many functions: regulates immunoglobulin production, promotes B
cell terminal differentiation into plasma cells, cooperatively expands CD8(+) T cells, promotes Th17 differentiation,
has inhibitory effects on antigen presentation by dendritic cells, and may be pro-apoptotic for B and NK cells.
Moreover, IL-21 has potent anti-tumor effects while it is also implicated in the development of autoimmune diseases.
IL-21 research may potentially be helpful in the treatment of a range of illnesses.

3. Autoimmune disease associated with increased cancer risk
Examples of autoimmune disorders associated with development of lymphomas are rheumatoid arthritis,
lupus erythematosus, Sjögren’s syndrome, Celiac disease and Hashimoto’s thyroidits.

3.1. Rheumatoid arthritis (RA)
Large granular lymphocyte proliferation may be present in some patients with RA and may sometimes
progress to T cell large granular lymphocyte leukemia. In addition, the risk of lymphoma is increased in patients with
RA, whether treated with methotrexate, or with other immunosuppressive agents or not.

3.2. Systemic lupus erythematosus
The risk of non-Hodgkin lymphomas appears to be increased four to five fold. In particular,
angioimmunoblastic T cell lymphoma may occur more often than expected.

3.3. Sjögren’s syndrome
Keratoconjunctivitis sicca refers to the ocular dryness associated with Sjögren’s syndrome. Both Sjögren’s
syndrome and keratoconjunctivitis sicca are caused by immune-mediated inflammation directed against the exocrine
glands of the eye and mouth. The histologic features include extensive lymphocytic infiltration, accompanied by
glandular and ductal atrophy. This lymphocytic infiltration is organized in germinal center-like structures. Salivary
glands are typically enlarged.

Sjögren’s syndrome is characterized by polyclonal B cell activation as well as lymphocytic infiltration of the
exocrine glands. This B cell activation predisposes some patients to the development of lymphoma. Most lymphomas

arise from a reactive infiltrate called lymphoepithelial sialadenitis or a benign lymphoepithelial lesion. The lifetime risk
of non-Hodgkin lymphoma is increased 16 to 44 times higher than expected, at approximately 5 percent.
A variety of clinical features appear to identify patients with Sjögren’s syndrome who are at increased risk
for lymphoma development: cutaneous vasculitis, peripheral neuropathy, rheumatoid factor positivity, type II
cryoglobulins. Risk factors identified in other studies include anti-Ro/SSA or anti-La/SSB antibody positivity and
infiltration of salivary glandular tissue by dendritic cells and macrophages that express the cytokines IL-12 and IL-18.

3.4. Celiac disease (Non-tropical sprue)
Serologic studies, now used to confirm the diagnosis of celiac disease, include the ELISA for IgA antibodies
to gliadin and the immunofluorescence test for IgA antibodies to endomysium, a structure in the smooth muscle
connective tissue. Elevated endomysium IgA antibodies are almost a pathognomonic finding. The target autoantigen
contained within the endomysium was identified as tissue transglutaminase. IgA-antibodies against endomysium and
the endomysial autoantigen tissue transglutaminase are both highly sensitive and specific. Widespread use of these
serologic tests has allowed earlier diagnosis, large scale population screening and thereby an improved understanding
of its epidemiology. These patients have an increased incidence of gastrointestinal non-Hodgkin lymphomas.

4. Autoimmune phenomenon with cancers – paraneoplastic syndromes
Neurological diseases are defined as paraneoplastic when they occur in increased frequency in patients with
cancer and are not related to a direct primary or metastatic effect of tumor, infection, metabolic abnormalities, or
toxicity of therapy 6, 7. Autoantibodies and evidence for cellular autoimmunity directed against neuronal, glial, or
muscle cell antigens have been identified in a number of paraneoplastic neurological disorders 8, 9. Over the past four
decades, different investigators identified and reported these disorders using a variety of names. This review employs
the nosology used by Posner (ref 7? Above): Paraneoplastic disorders are rare, but accurate diagnosis is important. For
patients with an occult malignancy, correct diagnosis may lead to the early diagnosis and treatment of the underlying
malignancy. Effective treatment of the neurologic disorder may improve neurologic dysfunction and improve quality
of life. Equally important, proper diagnosis of a paraneoplastic disorder spares the patient an extensive and expensive
search for alternative causes of the neurologic dysfunction.

4.1. Neurological

Examples of neurological paraneoplastic syndrome include: subacute sensory neuronopathy and
encephalomyeloneuritis,

limbic

encephalitis,

autonomic

neuropathy,

progressive

cerebellar

degeneration,

paraneoplastic vision loss, opsoclonus-myoclonus, motor neuron disorders, peripheral neuropathies, neuromuscular
junction disorders, muscle rigidity, dermatomyositis, polymyositis and movement disorders. Details are available in a
bigger textbook (Devita). The most commonly encountered neurological paraneoplastic syndromes in the clinic are
neuromuscular junction disorders, and dermatomyositis, polymyositis and will be discussed in detail as follows.

4.1.1. Neuromuscular Junction Disorders
4.1.1.1. Lambert-Eaton myasthenic syndrome
The autoimmune disorder of Lambert-Eaton myasthenic syndrome (LEMS) is associated with small cell lung
carcinoma in 50-60% of cases. Proximal weakness is a common presenting complaint, but bulbar symptoms are
uncommon. In most patients, LEMS is not a pure motor syndrome. Paresthesias are frequently reported sensory
findings. The abnormality of autonomic function has been called “cholinergic dysautonomia”. Patients may report dry
mouth or erectile dysfunction. Characteristic electrophysiologic abnormalities include augmentation of compound
motor action potentials with repetitive stimulation. Antibodies directed against protein epitopes in the voltage-gated
calcium channel of presynaptic neurons are present in most patients with LEMS. Passive transfer of antibody
reproduces the characteristic electrophysiologic abnormality in animal models of LES. Immunization with a
component of the P/Q-type calcium channel, synaptotagmin, produces autoantibodies and clinical disease in an animal
model of LES. Unlike other paraneoplastic syndrome, most patients with LES benefit from plasmapheresis and
immunosuppressive therapy. Drugs that increase presynaptic acetylcholine release may also decrease symptoms. 3,4diaminopyridine is one such agent with relatively minimal side effects. It has been postulated that patients with
paraneoplastic neurological syndromes such as LEMS have an improved tumour prognosis compared to other patients
with the tumour but without such neurological deficits 10.

4.1.1.2. Myasthenia Gravis
Typical myasthenia gravis is associated with thymoma in approximately 15% of cases, and autoantibodies
against contractile proteins of striated muscle are associated with increased probability of underlying thymoma. All
patients with myasthenia gravis should undergo thoracic imaging studies to identify thymic neoplasms. In patients with
thymoma, the myasthenia gravis often remit after thymectomy. In almost all cases, the thymoma is not invasive and
can be definitively treated by thymectomy. The author had come across a patient with unrecognized myasthenia gravis
and died from respiratory failure.

4.1.2. Dermatomyositis and polymyositis
These conditions are inflammatory myopathies characterized by the subacute development of proximal
muscle weakness, with or without pain and muscle tenderness. Both conditions are usually idiopathic. Approximately
10% are associated with cancer. The myopathy usually precedes the diagnosis of the underlying cancer. Although
most patients with dermatomyositis do not have cancer, patients with the disorder are probably at a higher risk for
cancer. When the characteristic findings are present in men older than 40 years, there is a higher incidence of
underlying cancer, and early detection should be the goal. Breast cancer is the most commonly associated cancer in
women, and lung and GI cancer in men. Association with tumors of the pancreas, melanoma, germ cell tumors,
nasopharyngeal carcinoma, and lymphoma has also been reported.

In addition to proximal symmetric muscle weakness and skin changes, there is usually an elevation in muscle
creatinine kinase. Electromyography is consistent with a myopathic process. A muscle biopsy usually shows
inflammatory infiltrates, necrotic fibres, and atrophic fibres, sometimes in a perifascicular pattern. An immunemediated intramuscular angiopathy leads to eventual ischemia and muscle fiber necrosis. IgG, IgM, and complement
deposits are found in small blood vessels. Cellular inflammatory infiltrates include B cells, macrophages, and CD4+ T
cells.

Immunosuppression has not been tested specifically in patients with myositis. It is unclear if antineoplastic
therapy leads to improvement in the muscle disease in the absence of concomitant immunosuppression. Both
dermatomyositis and polymyositis syndromes follows an inconsistent course and often independent of the cancer
outcome.

4.2. Others
Autoimmune hemolytic anemias are typically associated with B-cell malignancies, including chronic
lymphocytic leukemia and lymphoma, and arise secondary to immunoregulatory abnormalities in these diseases, rather
than to a direct secretion of tumor-derived substances 11. Hallmarks of this disorder disease are a positive direct
antiglobulin test (Coombs’) result, elevated reticulocyte count, decreased haptoglobin level, and elevated lactate
dehydrogenase level. Warm or cold antibody immune hemolytic anemias may be seen particularly in the small

lymphocytic type. Additional autoimmune phenomena, such as circulating anticoagulants (e.g., acquired von
Willebrand’s disease) may occur, especially in the small lymphocytic lymphomas.

Warm antibody hemolytic anemia is most commonly associated with lymphoma, chronic lymphocytic
leukemia, and mucin-producing adenocarcinoma. Cold agglutinin disease is most common in Waldenström's
macroglobulinemia and lymphomas 12. Autoimmune hemolytic anemia is rarely associated with solid tumors.
However, an association with ovarian, GI, lung, breast, and renal cell cancers has been reported also[Akard AGAIN].
Corticosteroid treatment appears to be less effective in autoimmune hemolytic anemia associated with carcinomas than
in those that are idiopathic or associated with lymphoid malignancies. The Coombs' test result may revert to negative
with control of the tumor.

5. Perspectives - Cancer vaccines

Immunotherapy for melanoma has undergone significant change since the first attempts to treat patients with
high dose IL-2. There are now strategies to boost patient antitumor immunity through vaccination, treatment with
agents that augment host immunity, and adoptive cell transfer 13. The first two strategies have yielded only limited
clinical success, but adoptive cell transfer therapy, particularly following a lymphodepleting, preconditioning regimen
has resulted in objective response rates approaching 50%.

Over the last century, vaccine studies have demonstrated that the human immune system, with appropriate
help, can limit or prevent infection against otherwise lethal pathogens 14. Encouraged by these results, success in
animal models and numerous well-documented reports of immune-mediated melanoma regression in humans,
investigators developed melanoma vaccines. However, despite considerable laboratory evidence for vaccine-induced
immune responses, clinical responses remain poor. Recent studies have elucidated several mechanisms that hinder or
prevent the creation of successful vaccines and suggest novel approaches to overcome these barriers. Unraveling the
mechanisms of autoimmunity, dendritic cell activation, regulatory T cells and Toll-like receptors will generate novel
vaccines that, when used in conjunction with standard adjuvant therapies, may result in improved clinical outcomes.

Balancing antitumor efficacy, autoimmunity, and reconstitution of a functioning immune system remain
challenging and potentially life-threatening issues. Nonmutated tissue differentiation antigens expressed by tumors are
attractive targets for cancer immunotherapy, but the consequences of a highly effective antitumor immune response on

self-tissue have not been fully characterized. The infusion of ex vivo expanded adoptively transferred
melanoma/melanocyte-specific CD8+ T cells that mediated robust tumor killing also induced autoimmune destruction
of melanocytes in the eye 15. This severe autoimmunity was associated with the up-regulation of MHC class I
molecules in the eye and high levels of IFN-gamma derived from both adoptively transferred CD8+ T cells and host
cells. Furthermore, ocular autoimmunity required the presence of the IFN-gamma receptor on target tissues. Data
compiled from >200 eyes and tumors in 10 independently performed experiments revealed a highly significant
correlation (P < 0.0001) between the efficacy of tumor immunotherapy and the severity of ocular autoimmunity.
Administration of high doses of steroids locally mitigated ocular autoimmunity without impairing the antitumor effect.
These findings have particular importance for immunotherapies directed against self-antigens and highlight the need
for targeting unique tumor antigens not expressed in critical tissues.
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